PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly

JI-MING YE,1 MIGUEL A. IGLESIAS,1 DAVID G. WATSON,1 BRONWYN ELLIS,1 LEONIE WOOD,1 PER BO JENSEN,2 RIKKE VEGGERBY SØRENSEN,2 PHILIP JUST LARSEN,2 GREGORY J. COONEY,1 KARSTEN WASSERMANN,3 AND EDWARD W. KRAEGEN1
1Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia; 2Rheoscience, DK-2100 Copenhagen; and 3Novo Nordisk, DK-2760 Målov, Denmark
Submitted 8 July 2002; accepted in final form 23 October 2002

Ye, Ji-Ming, Miguel A. Iglesias, David G. Watson, Bronwyn Ellis, Leonie Wood, Per Bo Jensen, Rikke Veggerby Sørensen, Philip Just Larsen, Gregory J. Cooney, Karsten Wassermann, and Edward W. Kraegen. PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284:E531–E540, 2003; 10.1152/ajpendo.00299.2002.—Peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonists lower lipid accumulation in muscle and liver by different mechanisms. We investigated whether benefits could be achieved on insulin sensitivity and lipid metabolism by the dual PPARα/γ agonist ragaglitazar in high-fat-fed rats. Ragaglitazar completely eliminated high-fat feeding-induced liver triglyceride accumulation and visceral adiposity, like the PPARα agonist Wy-14643 but without causing hepatomegaly. In contrast, the PPARγ agonist rosiglitazone only slightly lessened liver triglyceride without affecting visceral adiposity. Compared with rosiglitazone or Wy-14643, ragaglitazar showed a much greater effect (79%, P < 0.05) to enhance insulin’s suppression of hepatic glucose output. Whereas all three PPAR agonists lowered plasma triglyceride levels and lessened muscle long-chain acyl-CoAs, ragaglitazar and rosiglitazone had greater insulin-sensitizing action in muscle than Wy-14643, associated with a threefold increase in plasma adiponectin levels. There was a significant correlation of lipid content and insulin action in liver and particularly muscle with adiponectin levels (P < 0.01). We conclude that the PPARα/γ agonist ragaglitazar has a therapeutic potential for insulin-resistant states as a PPARγ ligand, with possible involvement of adiponectin. Additionally, it can counteract fatty liver, hepatic insulin resistance, and visceral adiposity generally associated with PPARα activation, but without hepatomegaly.

Peroxisome proliferator-activated receptor subtypes: adipokines; tissue lipids; insulin resistance

INSULIN RESISTANCE IS A FUNDAMENTAL DEFECT of type 2 diabetes. It is central to the insulin resistance syndrome characterized by hyperglycemia, hyperinsulinemia, dyslipidemia, obesity, and hypertension. There is increasing evidence to suggest that central adiposity (8) and fatty liver (30) are also important features of this syndrome. It is clear that a lipid accumulation in muscle and liver can cause the development of insulin resistance (4, 26, 41). Realization of the role of excess lipids in the pathogenesis of insulin resistance has led to various strategies to improve insulin sensitivity by lowering excess lipid accumulation in liver and muscle (32).

Peroxisome proliferator-activated receptors (PPAR) are nuclear transcription factors that include three subtypes: α, δ(β), and γ. PPARγ agonists, such as thiazolidinediones (TZDs), improve insulin action in peripheral tissues, attenuate hyperinsulinemia, and lower circulating levels of lipids. PPARγ agonists are highly expressed in adipocytes and mediate their differentiation. A major mechanism of the insulin-sensitizing action of PPARγ agonists results from the lowering of lipid supply to muscle and liver through a “lipid-stealing” by PPARγ-mediated effects in adipose tissue (22, 40). However, some concerns also arise over increases in fat mass and body weight associated with adipocyte proliferation (10, 14, 48).

Unlike PPARγ, PPARα mediates expression of genes regulating lipid oxidation (22). PPARα agonists, such as fibrates, have been used to treat hypertriglyceridemia and reduce cardiovascular risk (24). A number of studies in insulin-resistant animal models have shown marked decreases in liver triglyceride content and adiposity by PPARα agonists (6, 10, 16, 37). Using an euglycemic hyperinsulinemic clamp technique, our recent studies have clearly shown that, while exerting these effects, the PPARα agonist Wy-14643 can also lessen insulin resistance and muscle lipid accumulation in high-fat-fed rats. However, compared with a PPARγ agonist, the improvement of muscle insulin sensitivity by Wy-14643 was much smaller for similar reductions in muscle lipids (49). There are also opposite reports that PPARα deficiency may even protect...
insulin sensitivity (43). These data suggest that other factors, such as PPARγ-responsive adipokines, may be involved in the insulin-sensitizing action of PPARγ agonists. Currently, there is enormous interest in the potential of combined PPARα/γ agonists for enhancement of insulin action together with reductions in tissue lipid accumulation and central adiposity (22, 32).

Although possible benefits of combined PPARα/γ agonists have been suggested in earlier reports in genetically obese insulin-resistant models (13, 29, 34), their effects on insulin action in liver and muscle in relation to adipokines in a nutritional model of insulin resistance have not been demonstrated. Thus the aim of the present study was to investigate whether a dual PPARα/γ compound would exert additional beneficial effects on liver steatosis, adiposity, and insulin sensitivity compared with selective activation of PPARα or PPARγ. Lipid metabolism was examined in parallel, with particular focus on liver and muscle lipid content and central adiposity, and their relationship with leptin and adiponectin was investigated.

RESEARCH DESIGN AND METHODS

Study design. All experimental procedures were approved by the Animal Experimentation Ethics Committee (Garvan Institute/St Vincent’s Hospital, Sydney) and were in accordance with the National Health and Medical Research Council of Australia Guidelines on Animal Experimentation. Ragaglitazar (also known as NNC 61-0029 or DRF-37275) is a 2-ethoxy-3-[2-phenoxazin-10-y1-ethoxy]-phenyl]-propionic acid, structurally different from other PPARα and PPARγ ligands including TZDs, N-(2-benzoylephényl)-L-tyrosine derivatives, α-alkoxy-βphenylpropanoic acids, or fibrates (38). It is a full agonist of both PPARα and PPARγ. In vitro transactivation assay showed that the maximal activation of ragaglitazar on PPARγ was 117% (EC50: 0.57 μM) compared with rosiglitazone (100% with EC50 of 0.16 μM). For the stimulation of PPARα, ragaglitazar produces 97% (EC: 3.2 μM) of the maximal response induced by Wy-14643 (100% and EC50: 12.6 μM) (38).

Male Wistar rats supplied from the Animal Resources Centre (Perth, Australia) were conditioned at 22 ± 0.5°C with a 12:12-h day-night cycle (lights on 0600) for 1 wk in communal cages. They were fed ad libitum a standard chow diet containing 69% carbohydrate, 21% protein, 5% fat, fiber, vitamins, and minerals. After the acclimatization period, rats (~300 g) were fed the same chow diet or an isocaloric high-fat diet (350 kJ/day given at 1600) for 3 wk, as described previously (41). They were divided into five groups (n = 6–9/group unless otherwise indicated): insulin-sensitive chow-fed normal rats (CH-Con), and insulin-resistant high-fat-fed rats treated with vehicle (HF-Con), ragaglitazar (HF-Raga), rosiglitazone (HF-Rosi), or Wy-14643 (HF-WY). The nutrient composition of the fat diet, expressed as a percentage of energy, was 59% fat, 21% protein, 20% carbohydrate, with quantities of fibers, vitamins, and minerals equal to those in the chow-fed group. Previous studies showed that rats started to develop hepatic insulin resistance after 3 days of high-fat feeding (26). High-fat-fed rats were administered ragaglitazar, rosiglitazone, or Wy-14643 in the diet (each at 3 mg·kg⁻¹·day⁻¹) for 2 wk. Body weight and food intake were recorded daily, and no appetite-averting effect was observed for any of the compounds.

Assessment of PPARα and PPARγ activation in vivo. The mRNA expression levels of liver peroxisome bifunctional enzyme (PBE) and acyl-CoA oxidase (ACO) were determined to assess activation of PPARα. Total RNA was extracted from ~100 mg of liver using Tri-Reagent (Sigma, St. Louis, MO). Real-time LightCycler RT-PCR was employed to quantify ACO and PBE mRNA levels by use of the LightCycler Fast-Start DNA Master SYBR Green 1 kit (Roche Molecular Biochemicals, Mannheim, Germany) in a similar way as recently described (44). The primer combinations were: 5’-GAT TCA AGA CAA AGC CGT CCA AG-3’ and 5’-TCC ACC AGA GCA AGC TGG-3’ for ACO, 5’-GCC ACT TGA CAC ATT CCA GCT-3’ and 5’-GGG CTA CTC ATC TAT GGT GTC CAC-3’ for PBE. Expression levels were normalized to the expression levels of cyclophilin. Expression levels of phosphoenolpyruvate carboxykinase (PEPCK) mRNA in retinoperitoneal white adipose tissue, an indicator of PPARγ activation in adipocytes (42, 46), were determined by semi-quantitative RT-PCR, as described previously (20). Two primer sets (5 pmol of each oligo) were used simultaneously, one specific for the gene in question and the other specific for a freeze-clamped standard mixture of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward primer 5’-ACAGGATGAGGAACCGTGC-3’ and reverse primer 5’-CCTTGGCCCTTATGCTTC-3’ were used. For adipocyte protein-2 (aP2), forward primer 5’-AAGA-CAGCTCTCCTCTCAGAGGT-3’ and reverse primer 5’-TGAC-CAAATCCCACCTTACG-3’ were employed. PCR products were separated on a 6% polyacrylamide-7 M urea gel and analyzed using a phosphorimager and ImageQuant (Molecular Dynamics). Results are expressed as gene per internal standard. Activation of PPARγ in vivo was also assessed by plasma concentration of adiponectin as a marker (11) with a commercial radioimmunoassay kit (Linco, St. Louis, MO).

Experimental protocol. A week before the study, the left carotid artery and right jugular vein of rats were cannulated, and cannulas were exteriorized in the back of the neck under ketamine-xylazine (90:10 mg/kg ip) anesthesia. Rats were handled daily to minimize stress. On the study day between 0900 and 1000, after animals had been fasted for 5 h, the cannulas were connected to infusion apparatus (via the carotid line) and a blood-sampling syringe (via the jugular line). The sampling line was filled with sodium citrate (20.6 mM) to prevent clotting. After a period (50–60 min) of settling, two basal blood samples were collected for measurement of plasma parameters, as described previously (49). Rats were allowed to settle for ~1–2 h and then euthanized by pentobarbital sodium (~180 mg/kg). Muscles (red and white quadriceps) and heart were immediately freeze-clamped with aluminum tongs precooled in liquid nitrogen. Visceral (epidymal and retroperitoneal) fat and liver were weighed before being frozen in liquid nitrogen. Tissues were stored at −80°C for subsequent analyses for basal metabolites. The hyperinsulinenemic euglycemic clamp was performed at an insulin infusion rate of 0.25 U·kg⁻¹·h⁻¹ to elevate circulating insulin levels to approximately a half-maximal physiological concentration (25), with glucose infused at variable rates (GIR) to maintain euglycemia. After plasma glucose levels reached the steady state, a bolus of 2-deoxy-D-[2,6,3H]glucose and D-[U-14C]glucose was injected (iv) to determine glucose disappearance rate (Rd) and hepatic glucose output rate (HGO). After the clamp, tissues of interest were freeze-clamped to determine glucose uptake (Rg), glycogen, and lipid synthesis. Details of these measurements have been described previously (25, 41, 49).

Metabolic measurements. Glucose concentrations were determined using a glucose analyzer (YSI 2300, Yellow Springs, OH). Plasma free fatty acid (FFA) and triglyceride levels

AdJP-Endocrinol Metab • VOL 284 • MARCH 2003 • www.ajpendo.org
were determined using enzymatic colorimetric methods by commercial kits (Sigma). Plasma insulin and leptin levels were determined with radioimmunoassay kits (Linco). Tissue triglycerides were extracted by the method of Bligh and Dyer (7), and content was determined by a Peridochrom Triglyceride GPO-PAP kit (Boehringer Mannheim, Mannheim, Germany). Tissue content of glycogen (9) and long-chain acyl CoA (LCA)-CoAs (2) were determined as previously described.

Statistical analyses. All results are presented as means ± SE. A one-way analysis of variance (ANOVA) was used to assess the statistical significance across all groups. When tested as significant, a post hoc (Fisher paired least significant difference) test was used to establish differences between groups. All data were processed in Excel 5.0, and statistical analyses were performed using the Statview SE+Graphic Program (Abacus Concepts-Brain Power).

RESULTS

Activation of PPARα and PPARγ by ragaglitazar. Activation of PPARα is known to upregulate the expression of liver PBE, as shown in the HF-WY group (Fig. 1A). Although to a lesser extent, ragaglitazar treatment also led to a dramatic increase (3.1-fold) in PBE mRNA expression level in liver. Similarly, liver ACO mRNA levels were significantly increased ($P < 0.01$) in both HF-WY (35.8 ± 4.2) and HF-Raga (21.5 ± 5.9) groups but not in the HF-Rosi group (8.7 ± 3.2) compared with the CH-Con (8.9 ± 0.8) or HF-Con (7.3 ± 1.4) group. The expression levels of PEPCK mRNA in white adipose tissue were increased more than twofold in the HF-Raga group (Fig. 1B) in a pattern similar to the HF-Rosi group. These data indicated that both PPARα and PPARγ were activated by ragaglitazar, an observation that was also supported by a substantial (60%) reduction in plasma leptin levels in all treated groups (Fig. 1C). There was a positive correlation between plasma leptin concentrations and visceral fat weight among all five groups ($r = 0.75, P < 0.001$, data not shown). Recently, elevated plasma adiponectin concentration has been suggested as a specific indicator of PPARγ but not PPARα stimulation (11). Figure 1D shows that plasma adiponectin levels were raised approximately threefold in both the HF-Raga group and the HF-Rosi group. In addition, aP2 mRNA expression levels in retroperitoneal white adipose tissue were significantly higher in the HF-Raga group compared with the HF-Con or CH-Con group (2.9 ± 0.16 vs. 1.5 ± 0.14 or 1.2 ± 0.04 arbitrary units (AU), respectively, $P < 0.01$).

Effects on basal lipid and glucose metabolism. Table 1 shows basal metabolic parameters in all groups. Except for a small decrease in body weight gain in the HF-WY group (15% vs. HF-Con), there were no differences in weight gain among the groups. Compared with CH-Con rats, visceral fat mass was increased by 55% in the HF-Con group. This increase was prevented in HF-WY and HF-Raga groups but not in HF-Rosi rats. Thus the visceral adiposity of both the HF-Raga and HF-WY groups was significantly ($P < 0.01$) less (32 and 21%, respectively) than that of the HF-Rosi group. There was severe hepatomegaly in HF-WY (58% increase in liver weight vs. HF-Con), whereas neither ragaglitazar nor rosiglitazone altered liver weight. Associated with a small reduction in plasma glucose levels, elevated plasma insulin levels (34% vs. CH-Con) in HF-Con were abolished by all drugs. A similar pattern of decreases in plasma triglyceride levels by the three agonists (16–28%) was found despite their relatively
lower levels (vs. CH-Con) in HF-Con, an adaptive response due to increased lipid clearance (18). There was no significant effect on FFA levels in any of the treated groups.

High-fat feeding led to a threefold increase in liver triglyceride content compared with CH-Con (Fig. 2A). This was completely prevented by ragaglitazar (CH-Con: 7.0 ± 0.3 vs. HF-Raga: 7.0 ± 0.3 μmol/g, P >

<table>
<thead>
<tr>
<th></th>
<th>CH-Con</th>
<th>HF-Con</th>
<th>HF-Rosi (PPARγ)</th>
<th>HF-WY (PPARα)</th>
<th>HF-Raga (PPARα/γ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial body weight, g</td>
<td>307 ± 6</td>
<td>311 ± 3</td>
<td>312 ± 3</td>
<td>295 ± 4</td>
<td>315 ± 4</td>
</tr>
<tr>
<td>Final body weight, g</td>
<td>367 ± 3</td>
<td>368 ± 3</td>
<td>373 ± 4</td>
<td>347 ± 4</td>
<td>375 ± 4</td>
</tr>
<tr>
<td>Visceral fat wt, g</td>
<td>8.0 ± 0.6d</td>
<td>12.4 ± 0.4</td>
<td>11.6 ± 0.4b</td>
<td>7.9 ± 0.2c,e</td>
<td>9.2 ± 0.4d,f</td>
</tr>
<tr>
<td>Liver wt, g</td>
<td>14.7 ± 0.5</td>
<td>14.0 ± 0.3</td>
<td>13.9 ± 0.4</td>
<td>22.7 ± 0.4d,f</td>
<td>15.2 ± 0.2b</td>
</tr>
<tr>
<td>Plasma glucose, mM</td>
<td>7.9 ± 0.3d</td>
<td>8.9 ± 0.2</td>
<td>8.5 ± 2b</td>
<td>8.4 ± 1b,d</td>
<td>8.3 ± 0.1b,d</td>
</tr>
<tr>
<td>Plasma insulin, mU/l</td>
<td>38 ± 5d</td>
<td>51 ± 5</td>
<td>24 ± 2d</td>
<td>31 ± 3d</td>
<td>21 ± 2b,4g</td>
</tr>
<tr>
<td>Plasma triglyceride, mM</td>
<td>1.10 ± 0.10d</td>
<td>0.79 ± 0.04</td>
<td>0.57 ± 0.03b,d</td>
<td>0.66 ± 0.04*a, 0.59 ± 0.03b,d</td>
<td></td>
</tr>
<tr>
<td>Plasma FFAs, mM</td>
<td>0.60 ± 0.06</td>
<td>0.52 ± 0.04</td>
<td>0.45 ± 0.05</td>
<td>0.45 ± 0.02</td>
<td>0.48 ± 0.05</td>
</tr>
</tbody>
</table>

Data from the basal (CH-Con) and clamp subgroup were pooled together for body weight (n ≥ 13 group). HF-Con, high fat-vehicle; HF-Rosi, HF-WY, and HF-Raga, HF + peroxisome proliferator-activated receptors (PPAR)γ; rosiglitazone; α, Wy-14643; and α/γ, ragaglitazar; FFA, free fatty acids. Plasma parameters were obtained from 5 to 7-h-fasted cannulated rats (n = 6–9/group). *P < 0.05, **P < 0.01 vs. CH-Con; cP < 0.05, dP < 0.01 vs. HF-Con, eP < 0.05, fP < 0.01 vs. HF-Rosi; gP < 0.05, hP < 0.01 vs. HF-WY.

AJP-Endocrinol Metab • VOL 284 • MARCH 2003 • www.ajpendo.org
Although liver triglyceride content in the HF-Rosi group was marginally lower (by 14% vs. HF-Con), its level (19.2 ± 1.2 μmol/g) was approximately 2.6-fold higher (P < 0.001) than that of the normal CH-Con group or ragaglitazar-treated rats. The effect of ragaglitazar on lowering liver triglyceride content of high-fat-fed rats was also significantly greater than that of Wy-14643 (P < 0.05). As expected, liver LCA-CoA content (Fig. 2B) was also increased (by 108%) with high-fat feeding. Its levels in HF rats were unaltered by rosiglitazone or ragaglitazar but further increased in HF-WY by 108%. All three agonists decreased liver glycogen content, and the effect of Wy-14643 and ragaglitazar was greater than that of rosiglitazone (Fig. 2C). In contrast, all three PPAR agonists similarly affected these parameters in muscle. Compared with CH-Con, muscle levels of triglyceride (Fig. 2D) increased in HF-Con by 63% and 50%, respectively. None of the treatments altered muscle glycogen content (Fig. 2F).

**Whole body insulin sensitivity and lipids during hyperinsulinemic euglycemic clamp.** High-fat feeding induced insulin resistance, as evidenced by 50% of the clamp GIR (Fig. 3A). The underlying cause of insulin resistance was a combination of inhibited insulin-mediated glucose disposal rate (Rd) in peripheral tissues and impaired suppression of HGO. Compared with HF-Con, all three PPAR agonists increased the GIR (HF-Rosi: 51%, HF-WY: 39%, and HF-Raga: 66%) and Rd (15–22%). Increases in GIR and Rd values were not significantly different among the treated groups. Ragaglitazar substantially enhanced insulin’s suppressibility of HGO by 79%, whereas the apparent reduction of HGO induced by rosiglitazone or Wy-14643 did not reach statistical significance.

During the clamp, plasma triglyceride levels were also significantly lower in all treated rats compared with the HF-Con group, but only the HF-Raga group had lower FFA levels than the HF-Con group (Table 2). Plasma adiponectin levels were markedly higher (P < 0.01) in both HF-Rosi and HF-Raga groups than in HF-Con rats. These levels were most elevated in the HF-Raga group; they were 43% higher than those of the HF-Rosi group (P < 0.01).

**Insulin action in liver and associated changes in lipids.** As shown in Fig. 4A, the inhibition of insulin-stimulated glycogen synthesis by high-fat feeding was completely overcome by rosiglitazone and ragaglitazar, but not by Wy-14643. Although insulin-mediated de novo triglyceride synthesis from glucose remained largely inhibited in all high-fat-fed groups compared with CH-Con, there was a 41% increase in HF-Raga that was also significantly higher than in HF-Rosi or HF-WY (P < 0.05, Fig. 4B). As in the basal state, triglyceride content was reduced by all three drugs after the clamp (Table 2). However, its reduction in rosiglitazone-treated rats was relatively small (24%) and significantly less (P < 0.01) than the reduction in liver triglyceride content in groups treated with Wy-14643 (45%) and ragaglitazar (88%). Indeed, the effect of ragaglitazar was even greater than that of Wy-14643 (P < 0.05) and reverted liver triglyceride content to the normal level of chow-fed rats. When expressed as total hepatic triglyceride content per liver, the levels in the high-fat-fed groups (354 ± 32, 245 ± 25, 239 ± 37, and 75 ± 13 μmol per liver in HF-Con, HF-Rosi, HF-WY, and HF-Raga, respectively) were positively correlated with HGO (Fig. 5A). Both liver total triglyceride content and HGO were negatively correlated with plasma adiponectin levels (Fig. 5, B and C).

**Insulin action in peripheral tissues and associated changes in lipids.** As illustrated in Table 2, rosiglitazone and ragaglitazar enhanced insulin-mediated R_g in both red (65 and 150%) and white (168 and 113%) muscles, whereas improvement of R_g in HF-WY oc-
curred mainly in white muscle (61%). All three agonists increased the \( R_g \) in white adipose tissue (WAT), with the greatest improvement observed in HF-Raga (HF-Rosi: 79%, HF-WY: 74%, and HF-Raga: 147% above HF-Con). Compared with the HF-Rosi group, the \( R_g \) values in the HF-Raga group were 30 and 38% higher in red muscle and WAT, respectively (\( P < 0.05 \)), whereas white muscle showed similarly enhanced \( R_g \) in these two groups. Compared with Wy-14643, ra-
gaglitazar was clearly much more effective in enhanc-
ing muscle insulin sensitivity enhanced by rosiglitazone and ragaglitazar. In comparison, there was only a small improvement of glucose incorporation into tri-
glyceride by the three agonists (Fig. 4D), suggesting that de novo lipogenesis from glucose contributes very little to the enhanced insulin action in muscle. After the clamp, muscle LCA-CoA content was markedly decreased in all groups (\( P < 0.01 \) vs. basal values), and their levels remained significantly lower than the level of HF-Con (Table 2). There was a negative correlation between muscle LCA-CoA content and insulin-stimu-
lated muscle \( R_g \) (Fig. 5D) and plasma adiponectin levels (Fig. 5E). In contrast, insulin-stimulated muscle \( R_g \) was positively correlated with plasma adiponectin levels (Fig. 5F).

Table 2. Plasma and tissue metabolites during the hyperinsulinemic euglycemic clamp

<table>
<thead>
<tr>
<th></th>
<th>CH-Con</th>
<th>HF-Con</th>
<th>HF-Rosi (PPARγ)</th>
<th>HF-WY (PPARα)</th>
<th>HF-Raga (PPARα/γ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma triglyceride, mM</td>
<td>0.52 ± 0.09</td>
<td>0.50 ± 0.04</td>
<td>0.40 ± 0.04*</td>
<td>0.41 ± 0.03*</td>
<td>0.31 ± 0.02b, d, g</td>
</tr>
<tr>
<td>Plasma FFAs, mM</td>
<td>0.33 ± 0.06c</td>
<td>0.21 ± 0.03</td>
<td>0.27 ± 0.04</td>
<td>0.23 ± 0.02</td>
<td>0.13 ± 0.03b, i, g</td>
</tr>
<tr>
<td>Plasma adiponectin, μg/ml</td>
<td>3.8 ± 0.3</td>
<td>3.7 ± 0.5</td>
<td>6.5 ± 0.8c</td>
<td>4.1 ± 0.5*</td>
<td>9.3 ± 0.6c, f, b</td>
</tr>
<tr>
<td>Muscle LCA-CoAs, nmol/g</td>
<td>3.8 ± 0.3d</td>
<td>11.8 ± 1.7</td>
<td>7.7 ± 0.8c</td>
<td>8.9 ± 0.6b, c</td>
<td>7.0 ± 1.2d, g</td>
</tr>
<tr>
<td>Liver TG, μmol/g</td>
<td>7.3 ± 1.2d</td>
<td>23.3 ± 1.6</td>
<td>17.8 ± 2.1bc</td>
<td>10.4 ± 1.6df</td>
<td>5.0 ± 0.8d, f, g</td>
</tr>
<tr>
<td>Red muscle ( R_g ), μmol·100 g(^{-1})·min(^{-1})</td>
<td>34 ± 4d</td>
<td>20 ± 2</td>
<td>33 ± 3d</td>
<td>24 ± 2ks</td>
<td>43 ± 4d, a, h</td>
</tr>
<tr>
<td>White muscle ( R_g ), μmol·100 g(^{-1})·min(^{-1})</td>
<td>6.0 ± 0.5</td>
<td>4.1 ± 0.5</td>
<td>11.0 ± 1.7bd</td>
<td>6.6 ± 0.6ce</td>
<td>8.7 ± 1.0d</td>
</tr>
<tr>
<td>WAT ( R_g ), μmol·100 g(^{-1})·min(^{-1})</td>
<td>2.9 ± 0.4c</td>
<td>1.9 ± 0.2</td>
<td>3.4 ± 0.4d</td>
<td>3.3 ± 0.2d</td>
<td>4.7 ± 0.4bd, g</td>
</tr>
</tbody>
</table>

Plasma values were averaged of 2 samples during steady state during the clamp. LCA-CoAs, long-chain acyl-CoAs; TG, triglycerides; \( R_g \), glucose uptake; WAT, white adipose tissue. *\( P < 0.05 \), **\( P < 0.01 \) vs. CH-Con; *\( P < 0.05 \), **\( P < 0.01 \) vs. HF-Con, *\( P < 0.05 \), **\( P < 0.01 \) vs. HF-Rosi; *\( P < 0.05 \), **\( P < 0.01 \) vs. HF-WY (\( n = 6–9 \) group).

Fig. 4. Insulin-stimulated glycogen and triglyceride synthesis in liver (A and B) and muscle (C and D) during the hyperinsulinemic euglycemic clamp. A and C: glycogen synthesis measured by [\( ^{14} \)C]glucose incorporation into glycogen; B and D: triglyceride synthesis measured by [\( ^{14} \)C]glucose incorporation into triglyceride. #\( P < 0.05 \), ##\( P < 0.01 \) vs. CH-Con; *\( P < 0.05 \), **\( P < 0.01 \) vs. HF-Con; +\( P < 0.05 \), ++\( P < 0.01 \) vs. HF-Rosi; $\( P < 0.05 \) vs. HF-WY.
DISCUSSION

The present study demonstrates that combined activation of PPARα/γ markedly counteracts high-fat feeding-induced hepatic steatosis and visceral adiposity in combination with a marked improvement of insulin action. With use of a hyperinsulinemic euglycemic clamp technique and double glucose tracers, in parallel with determinants of lipid metabolism, we have clearly demonstrated additional benefits on liver insulin sensitivity of dual activation of PPARα/γ compared with selective activation of PPARγ. Interestingly, although stimulating PPARα, the PPARα/γ agonist ragaglitazar did not cause hepatomegaly. As seen for selective PPARγ agonists, dual PPARα/γ activation substantially increased circulating levels of adiponectin.

Liver steatosis is a characteristic in patients with type 2 diabetes and obesity (39) and is closely associated with the insulin resistance syndrome (30). Our first important finding was the complete prevention of high-fat feeding-induced liver steatosis by the dual PPARα/γ activator ragaglitazar and associated substantial enhancement of insulin’s suppressibility of HGO. It appears that the PPARα agonist ragaglitazar decreased liver triglyceride content primarily by activating PPARα, as indicated by increased expression levels of liver PBE and ACO mRNA, in a similar way to Wy-14643. These results are consistent with the finding in obese Zucker rats that the PPARα/γ coligand KRP-297 reduces liver triglyceride content more effectively than rosiglitazone because it stimulates FFA oxidation and inhibits lipogenesis (34). There is evidence that rats treated with PPARα activators have a sustained increase in uncoupling protein (UCP)2 mRNA expression in the liver and particularly the small intestine, where UCP2 is abundantly expressed (35). Further studies are required to investigate whether this may provide a plausible mechanism to facilitate energy depletion of the increased fatty acid oxidation mediated by PPARα or combined PPARα/γ activation. In addition to PPARα, PPARγ-mediated responses also appear to contribute to the effects of ragaglitazar on liver. Like rosiglitazone, ragaglitazar improved insulin-mediated hepatic glycogen synthesis. More importantly, both ragaglitazar and rosiglitazone dramatically increased plasma levels of adiponectin, a specific PPARγ-induced adipokine (11) that has recently been shown to enhance insulin action in liver (5). Although adiponectin has been shown to promote...
Our results from ragaglitazar indicate that PPARγ-mediated response in rodents. However, it is not clear how important hepatic manner due to peroxisome proliferation. This interaction of liver size (or peroxisome proliferation). This interaction was that ragaglitazar almost completely counteracted a high-fat feeding-induced increase in visceral fat mass, an effect clearly different from that of rosiglitazone. Although subcutaneous fat depots have been shown to be more responsive to PPARγ activation than visceral depots in humans (1) and to potentially influence fat distribution, a recent study showed that ragaglitazar does not alter subcutaneous fat weight (27). This finding is of potential significance because of body weight gain induced by PPARγ agonists alone (10, 14, 48). Additionally, insulin resistance is closely correlated with visceral fat mass in rats (23) and humans (8), and reduction of visceral fat can ameliorate insulin resistance, particularly in the liver (4, 16, 17). PPARγ activators, such as fibrate and GW-9578, have been shown to reduce adiposity in obese rodents (10, 16). In keeping with these previous findings, the present study also found a reduction in visceral adiposity by the selective PPARγ agonist Wy-14643. Because dual PPARα/γ agonists (such as KRP-297) can increase PFA oxidation (34), like selective PPARγ agonists, it is highly likely that ragaglitazar reduces visceral adiposity development via stimulating PPARα-mediated PFA oxidation. It may be argued that the lack of overall increased visceral fat mass upon combined PPARα/γ activation is associated with a lack of de novo adipogenesis. However, like other dual PPARα/γ agonists (34), ragaglitazar stimulated, rather than inhibited, adipogenesis, as indicated by an increase in adipogenesis in adipose tissue compared with untreated high-fat-fed rats. This suggests that the less visceral adiposity in the ragaglitazar-treated group was not associated with reduced adipogenesis. Although PPARγ-responsive adipokines, such as leptin and adiponectin, may potentially influence body adiposity (15), they do not seem to contribute to the reduced visceral adiposity by ragaglitazar, because rosiglitazone exerted similar effects on these adipokine plasma concentrations but without altering visceral adiposity.

Despite apparent responses mediated by PPARα, ragaglitazar did not cause hepatomegaly. Most pure PPARα agonists cause hepatomegaly in rodents in a species-specific manner due to peroxisome proliferation (19). However, it is not clear how important hepatomegaly is for PPARα-mediated response in rodents. Our results from ragaglitazar indicate that PPARα-mediated effects in the liver do not rely on enlargement of liver size (or peroxisome proliferation). This interpretation is also supported by the effects of fish oil in rats, where PPARα is activated in the absence of hepatomegaly (Cooney GJ and Kraegen EW, unpublished observations). There are also reports that coactivation of PPARα/δ (33) or PPARα/γ (34) does not induce hepatomegaly. Consistent with these observations, PPARα-mediated lipid oxidation in mitochondria has been shown to be independent of peroxisome proliferation (28). It is possible that activation of PPARγ interacts to prevent PPARα-induced hepatomegaly or, alternatively, the stimulation of PPARα by ragaglitazar was not strong enough to produce hepatomegaly. Regardless of the mechanism, the observed effects of ragaglitazar may have significant implications, because PPARα agonists such as fibrates also lower lipids in the absence of hepatomegaly in humans.

Like rosiglitazone, ragaglitazar strongly enhanced insulin action in muscle, a result similar to that previously reported in other insulin-resistant models by dual PPARα/γ agonists such as JTT-501 (29) and LY-465608 (13). These data suggest that PPARγ-mediated effects may be mainly responsible for the insulin-sensitizing action in muscle induced by ragaglitazar, because the effects of PPARα agonist Wy-14643 upon insulin-mediated Rg were relatively small and mainly seen in white muscle. We have previously postulated that PPARγ activation may also improve muscle insulin action by mechanisms independent of lipid stealing (49). PPARγ agonists can alter adipokines, which may affect insulin sensitivity (21). Because leptin and adiponectin have been shown to improve insulin action and increase lipid oxidation in muscle (15, 31, 45), we examined the effects of their circulating levels. The suppressed plasma leptin levels in all treated groups indicate that leptin is unlikely to be involved in PPARα-mediated insulin sensitization in muscle. Whereas PPARγ activation is known to suppress leptin expression (12), the decreased plasma leptin levels in the HF-WY group may result from reduced visceral fat mass in a way similar to surgical removal (4). In contrast, plasma adiponectin concentrations were threefold higher in HF-Rosi and HF-Raga rats, and there was a strong correlation of plasma adiponectin levels with muscle LCA-CoA content, and even more so with insulin-mediated Rg. These results strongly suggest an important role of adiponectin in PPARγ-mediated lipid metabolism and insulin sensitization, as recently proposed (15). However, the distinct effects of ragaglitazar and rosiglitazone on liver triglyceride content, visceral adiposity, and HGO during the hyperinsulinemic clamp suggest that these improvements could not be entirely explainable by the elevated systemic adiponectin concentrations. Furthermore, as these effects were substantially similar to those caused by Wy-14643 without a significant increase in plasma adiponectin concentrations, PPARα-mediated changes may be more likely to play an important role in reducing liver triglyceride content and visceral adiposity.

We recognized that limitations might occur for comparisons based on a single dose and that it could be argued that greater responses might be obtained at higher doses of rosiglitazone and Wy-14643. However, rosiglitazone-induced responses in this study were almost the same as those obtained by our laboratory under similar conditions at a 3.8-fold high dose admin-
istered by oral gavage (36). In terms of Wy-14643, our
pilot study showed that higher doses (e.g., 10
mg·kg⁻¹·day⁻¹) caused appetite-averting effects with
no further improvement of insulin sensitivity (climp
GIR: 19.6 ± 4.2 mg·kg⁻¹·min⁻¹, n = 3). These data led
us to believe that the responses produced by both
rosiglitazone and Wy-14643 had reached their plateau.
Similar degrees of activation of PPARγ by rosiglitazone
and ragaglitazar in the present study were suggested
by similar plasma adiponectin levels. It was also no-
bted that rosiglitazone and ragaglitazar in the present study were suggested
by similar plasma adiponectin levels. It was also no-

In summary, the present study compared three types of
PPAR agonists at the levels of whole body and
tissues. The results demonstrated that combined activa-
tion of PPARα/γ in the insulin-resistant high-fat-fed
rat exerts additional benefits to counteract fatty liver,
hepatic insulin resistance, and visceral adiposity while
maintaining at least equivalent effectiveness to en-
hance muscle insulin action and elevate circulating
adiponectin concentrations to selective PPARγ stimula-
tion. There is a close association between elevated
plasma adiponectin levels and improved insulin action
in liver and muscle induced by PPARα/γ (and PPARγ)
activation. Our results suggest that the PPARα/γ ago-
nist ragaglitazar may have significant therapeutic poten-
tial in insulin-resistant states, with additional ben-
efits of ameliorating fatty liver, hepatic insulin
resistance, and adiposity without any involvement of
increased liver mass compared with PPARγ activation
alone.

We thank J. Edema, Mercedes Ballesteros, and Nanna Hansen for
excellent technical assistance, and the Biological Testing Facility
staff for supportive animal care and maintenance.

This study was supported by the Australian National Health and
Medical Research Council.

REFERENCES

1. Adams M, Montague CT, Prins JB, Holder JC, Smith SA,
Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee
VK, and O’Rahilly S. Activators of peroxisome proliferator-
activated receptor gamma have depot-specific effects on human

2. Antinucci PA, Segall L, Pretinki M, McGarry JD, and New-
gard CB. Molecular or pharmacologic perturbation of the link
between glucose and lipid metabolism is without effect on glu-
cose-stimulated insulin secretion. A re-evaluation of the long-
chain acyl-CoA hypothesis. J Biol Chem 273: 16146–16154,
1998.

3. Aoki K, Saito T, Satoh S, Mukasa K, Kaneshiro M, Ka-
wasaki S, Okamura A, and Sekihara H. Dehydroepiandro-
terone suppresses the elevated hepatic glucose-6-phosphatase
and fructose-1,6-bisphosphatase activities in C57BL/Kaj-db/db
mice: comparison with troglitazone. Diabetes 48: 1579–1585,
1999.

Rossetti L. Surgical removal of visceral fat reverses hepatic

5. Berg AH, Combs TP, Du X, Brownlee M, and Scherer PE.
The adipocyte-secreted protein Acrp30 enhances hepatic insulin

M, Ventre J, Wu MS, Berger GD, Mosley R, Marquiss R,
Santini C, Sahoo SP, Tolman RL, Smith RG, and Moller DE.
Novel peroxisome proliferator-activated receptor (PPAR)
gamma and PPARdelta ligands produce distinct biological ef-

7. Bligh EG and Dyer WJ. A rapid method of total lipid extraction

8. Carey DG, Jenkins AB, Campbell LV, Freund J, and Ch-
isholm DJ. Abdominal fat and insulin resistance in normal and
overweight women: direct measurements reveal a strong rela-
tionship in subjects at both low and high risk of NIDDM. Diabe-

9. Chan TM and Exton JH. A rapid method for the determination
of glycogen content and radioactivity in small quantities. Anal

10. Chaput E, Saladin R, Silvestre M, and Edgar AD. Fenofi-
brate and rosiglitazone lower serum triglycerides with opposing
effects on body weight. Biochem Biophys Res Commun 271:

11. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ,
Zhang BB, Tanen M, Berg AH, O’Rahilly S, Savage DB,
Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz
BJ, Charron MJ, Scherer PE, and Moller DE. Induction of
adipocyte complement-related protein of 30 kilodaltons by
PPARgamma agonists: a potential mechanism of insulin sensi-

12. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong
K, Saladin R, Hamann LG, Staels B, Briggs MR, and Au-
werx J. Thiazolidinediones repress ob gene expression in re-
dents via activation of peroxisome proliferator-activated recep-

13. Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Mon-
trose CR, Bronzwick JI, Misener EA, Bean JS, Benesch WR,
RJ, Tyhonas JS, Dana SL, Bilakovics JM, Patronetti JR Jr,
Ogilvie KM, Liu S, and Kauffman RF. A tailored therapy for
the metabolic syndrome: the dual peroxisome proliferator-acti-
ivated receptor-alpha/gamma agonist LY456608 ameliorates in-
sulin resistance and diabetic hyperglycemia while improving
cardiovascular risk factors in preclinical models. Diabetes 51:

Effect of metformin and rosiglitazone combination therapy in
patients with type 2 diabetes mellitus: a randomized controlled

15. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson
MR, Yen FT, Bihain BE, and Lodish HF. Proteolytic cleavage
product of 30-kDa adipocyte complement-related protein in-
creases fatty acid oxidation in muscle and causes weight loss in

Derudas B, Herbert JM, Vinogar DA, Willson TM, Fru-
chart JC, Berge RR, and Staels B. Peroxisome proliferator-
activated receptor alpha activators improve insulin sensitivity

17. Hansen PA, Han DH, Nolte LA, Chen M, and Holloszy JO.
DHEA protects against visceral obesity and muscle insulin
resistance in rats fed a high-fat diet. Am J Physiol Regul Integr

Increased efficiency of fatty acid uptake contributes to lipid
accumulation in skeletal muscle of high-fat-fed insulin-resistant

19. Holden PR and Tugwood JD. Peroxisome proliferator-acti-
vated receptor alpha: role in rodent liver cancer and species

mRNA profiling of rat islet tumors reveals nck 6.1 as a beta-cell-


